Adherence to recommendations for the use of antifungal agents in a tertiary care hospital

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 10, 2012, Pages 2506-2513

  Nivoix, Yasmine ^a   Launoy, Anne ^a   Lutun, Philippe ^a   Moulin, Jean Charles ^a   Phai pang, Katy Anna ^a   Fornecker, Luc Matthieu ^a   Wolf, Michèle ^a   Levěque, Dominique ^a   Letscher Bru, Valérie ^b   Beretz, Laurence ^a   Ubeaud Sequier, Geneviève ^a,c   Herbrecht, Raoul ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b Institut de Parasitologie et de Pathologie Tropicale   (France)

^c UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Antifungal therapy; Aspergillosis; Candidiasis; Guidelines; Invasive fungal infections

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; TERBINAFINE; VORICONAZOLE;

ADULT; AGED; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLOSIS; CANDIDIASIS; DRUG LABELING; DRUG USE; FEMALE; HEMATOLOGY; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NONHUMAN; ONCOLOGY WARD; PRACTICE GUIDELINE; PRESCRIPTION; PROPHYLAXIS; RETROSPECTIVE STUDY; SURVIVAL RATE; TERTIARY HEALTH CARE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; DRUG PRESCRIPTIONS; FEMALE; FRANCE; GUIDELINE ADHERENCE; HEMATOLOGIC NEOPLASMS; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; MYCOSES; ONCOLOGY SERVICE, HOSPITAL; RETROSPECTIVE STUDIES; TERTIARY CARE CENTERS; YOUNG ADULT;

EID: 84866609623     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks256     Document Type: Article

References (30)

1. Herbrecht R, Flückiger U, Gachot B et al. Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients. Eur J Cancer Suppl 2007; 5: 49-59.
2. Maertens JA, Frère P, Lass-Flörl C et al. Primary antifungal prophylaxis in leukemia patients. Eur J Cancer 2007; 5: 43-9.
3. Marchetti O, Cordonnier C, Calandra T. Empirical antifungal therapy in neutropaenic cancer patients with persistent fever. Eur J Cancer 2007; 5: 32-43.
4. Maertens J, Marchetti O, Herbrecht R et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 Update. Bone Marrow Transplant 2011; 46: 709-18.
5. Rex JH, Walsh TJ, Sobel JD et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 662-78.
6. Stevens DA, Kan VL, Judson MA et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 696-709.
7. Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-60.
8. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35.
9. Saag MS, Graybill RJ, Larsen RA et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 710-8.
10. Gutiérrez F, Wall PG, Cohen J. An audit of the use of antifungal agents. J Antimicrob Chemother 1996; 37: 175-85.
11. Pavese P, Ouachi Z, Vittoz JP et al. Adequacy of new systemic antifungal agents prescriptions in a teaching hospital. Med Mal Infect 2007; 37 Suppl 3: S223-8.
12. Raymond S, Henon T, Grenouillet F et al. Clinical audit on the use of expensive systemic antifungals in the Besançon University Hospital. Med Mal Infect 2009; 39: 125-32.
13. Herbrecht R, Berceanu A. b-D-Glucan detection test: a step toward preemptive therapy for fungal infections in leukemic patients? Clin Infect Dis 2008; 46: 886-9.
14. Segal BH, Herbrecht R, Stevens DA et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis. 2008; 47: 674-83
15. Eggimann P, Ostrosky-Zeichner L. Early antifungal intervention strategies in ICU patients. Curr Opin Crit Care 2010; 16: 465-9.
16. Playford EG, Lipman J, Sorrell TC. Prophylaxis, empirical and preemptive treatment of invasive candidiasis. Curr Opin Crit Care 2010; 16: 470-4.
17. De Pauw BE, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
18. Nivoix Y, Velten M, Letscher-Bru V et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 2008; 47: 1176-84.
19. Horn D, Neofytos D, Fishman J et al. Use of the PATH Alliance database to measure adherence to IDSA guidelines for the therapy of candidemia. Eur J Clin Microbiol Infect Dis 2007; 26: 907-14.
20. Patel M, Kunz DF, Trivedi VM et al. Initial management of candidemia at an academic medical center: evaluation of the IDSA guidelines. Diagn Microbiol Infect Dis 2005; 52: 29-34.
21. Aliyu SH, Enoch DA, Abubakar II et al. Candidaemia in a large teaching hospital: a clinical audit. QJM 2006; 99: 655-63.
22. Garey KW, Neuhauser MM, Bearden DT et al. Evaluation of antifungals in the surgical intensive care unit: a multi-institutional study. Mycoses 2006; 49: 226-31.
23. Leroy O, Mira JP, Montravers P et al. Invasive candidiasis in ICU: analysis of antifungal treatments in the French study AmarCand. Ann Fr Anesth Reanim 2008; 27: 999-1007.
24. Natsch S, Steeghs MH, Hekster YA et al. Use of fluconazole in daily practice: still room for improvement. J Antimicrob Chemother 2001; 48: 303-10.
25. Garey KW, Pai MP, Suda KJ et al. Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines. Pharmacoepidemiol Drug Saf 2007; 16: 919-27.
26. Garey KW, Turpin RS, Bearden DT et al. Economic analysis of inadequate fluconazole therapy in non-neutropenic patients with candidaemia: a multi-institutional study. Int J Antimicrob Agents 2007; 29: 557-62.
27. Walsh TJ, Raad I, Patterson TF et al. Treatmentof invasiveaspergillosiswith posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44: 2-12.
28. Trifilio S, Pennick G, Pi J et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007; 109: 1532-5.
29. Zilberberg MD, Kollef MH, Arnold H et al. Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study. BMC Infect Dis 2010; 10: 150.
30. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49: 3640-5.